迪安诊断(300244) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥3,546,935,832.26, an increase of 18.27% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥505,643,776.08, reflecting a growth of 27.05% year-on-year[4] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥531,233,840.66, up 42.16% from the previous year[4] - The company achieved a total revenue of ¥9,338,149,453.42 for the first nine months of 2021, a 24.97% increase compared to the same period last year[12] - The net profit attributable to shareholders for the first nine months of 2021 was ¥1,232,732,701.26, up 37.07% year-on-year[12] - Net profit for the quarter was ¥1,494,473,167.81, representing a 35% increase from ¥1,107,412,962.29 in the previous year[34] - The net profit attributable to the parent company was CNY 1,232,732,701.26, an increase from CNY 899,354,586.42 in the previous period, representing a growth of approximately 37.1%[37] - The total comprehensive income attributable to the parent company was CNY 1,232,732,701.26, compared to CNY 899,354,586.42 in the previous period, indicating a significant increase[37] Earnings and Shareholder Value - The company's basic earnings per share for Q3 2021 was ¥0.8149, a rise of 27.03% compared to the same period last year[4] - The basic earnings per share rose to CNY 1.9868 from CNY 1.4495, reflecting a growth of about 37%[37] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥15,341,939,927.49, representing a 23.74% increase from the end of the previous year[4] - Total assets reached ¥15,341,939,927.49, up from ¥12,398,749,686.11 year-over-year, reflecting a growth of 23.5%[30] - Total liabilities increased to ¥7,688,668,888.67, compared to ¥6,369,960,305.25 in the previous year, marking a rise of 20.7%[30] - The equity attributable to shareholders of the parent company was CNY 4,697,870,632.84, remaining unchanged from the previous period[51] Cash Flow and Investments - Cash inflows from operating activities totaled CNY 8,766,159,447.67, up from CNY 6,834,924,774.94, marking an increase of approximately 28.4%[40] - Cash outflows from operating activities were CNY 8,292,540,839.98, compared to CNY 6,404,596,463.00 in the previous period, resulting in a net cash flow from operating activities of CNY 473,618,607.69, up from CNY 430,328,311.94[40] - Cash inflows from investing activities were CNY 356,975,604.93, compared to CNY 158,844,631.40 in the previous period, showing a significant increase[42] - Cash inflows from financing activities amounted to CNY 4,486,209,464.19, an increase from CNY 3,537,155,102.96 in the previous period[42] Research and Development - Research and development expenses for Q3 2021 were ¥281,760,860.48, an increase of 41.43% year-on-year, reflecting the company's commitment to its "Leading the Future" strategy[12] - R&D expenses increased to 282 million yuan, a 41% rise compared to the same period last year, focusing on molecular diagnostics, pathology, mass spectrometry, and trace elements[13] Business Segments - The diagnostic services business achieved revenue of 4.556 billion yuan, a year-on-year increase of 23%, with revenue excluding COVID-19 business at 2.916 billion yuan, up 37% year-on-year and 36% compared to 2019[13] - The diagnostic products business generated revenue of 5.291 billion yuan, reflecting a 26% year-on-year growth[13] - The channel agency business saw stable growth, with revenue of 4.904 billion yuan, a 25% increase year-on-year and 21% compared to 2019[13] - The self-produced products business experienced rapid growth, achieving revenue of 387 million yuan, a 51% increase year-on-year[13] Operational Metrics - Operating cash flow improved significantly, with a net increase to 474 million yuan[13] - The company reported a significant increase in accounts receivable, which reached ¥6,084,306,440.79, a growth of 34.31% due to expanded business operations[9] - Accounts receivable rose to approximately 6.084 billion yuan, compared to 4.530 billion yuan at the end of 2020[24] - Inventory increased to approximately 1.324 billion yuan, up from 1.123 billion yuan at the end of 2020[24]